OTEurope

Fovea and Genzyme enter gene therapy collaboration

Dec 3, 2007

Fovea Pharmaceuticals has entered into a collaborative research agreement with Genzyme Corporation.

Fovea Pharmaceuticals has entered into a collaborative research agreement with Genzyme Corporation.

The alliance is based around Fovea's proprietary high content technology platform that allows the identification of new targets involved in photoreceptor degeneration in retinal dystrophies.

The two companies will collaborate to develop gene related therapies using this technology together with Genzyme's gene delivery techniques.

Related Videos

Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity

EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme

Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments

Related Content

Federal investment and regulatory benefits draw biotech firms to Switzerland

Preservative-free latanoprost as effective as BAK-preserved latanoprost

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Late spring heatwave poses vision risk to populations across Europe

Stating the facts about combination myopia management treatments

WHO validates Benin and Mali for eliminating trachoma as public health problem

Federal investment and regulatory benefits draw biotech firms to Switzerland

Preservative-free latanoprost as effective as BAK-preserved latanoprost

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Late spring heatwave poses vision risk to populations across Europe

Stating the facts about combination myopia management treatments

WHO validates Benin and Mali for eliminating trachoma as public health problem

Federal investment and regulatory benefits draw biotech firms to Switzerland

Preservative-free latanoprost as effective as BAK-preserved latanoprost

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Late spring heatwave poses vision risk to populations across Europe

Stating the facts about combination myopia management treatments

WHO validates Benin and Mali for eliminating trachoma as public health problem

Related Content

An airport departure board shows a flight to Geneva is boarding. Image credit: ©WD Stockphotos – stock.adobe.com

Federal investment and regulatory benefits draw biotech firms to Switzerland

The country is home to 20% of biotechs headquartered in Europe.

Preservative-free latanoprost as effective as BAK-preserved latanoprost

Preservative-free latanoprost as effective as BAK-preserved latanoprost

Therapeutic has fewer adverse effects in patients with POAG and OHT, study results show

UK patients with vision loss confused by ‘disjointed’ benefits registration system

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Accessibility obstacles could prevent those with sight loss from receiving support and care.

Late spring heatwave poses vision risk to populations across Europe

Late spring heatwave poses vision risk to populations across Europe

What ophthalmologists want patients to know ahead of UK bank holiday.

Stating the facts about combination myopia management treatments

Stating the facts about combination myopia management treatments

Growing evidence supports dual therapy to slow progression.

WHO validates Benin and Mali for eliminating trachoma as public health problem

WHO validates Benin and Mali for eliminating trachoma as public health problem

The countries join 15 other nations that have eliminated the disease.

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.